20 Clinical pearls: Viral hepatitis

Infections in Medicine

Volumn 20, Issue 6, 2003, Pages 281-289

  Reiser, Markus ^a   Lauer, Georg M ^b,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hepatitis; Interferon; Vaccination

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; RIBAVIRIN; TUBERCULOSTATIC AGENT;

ARTICLE; AUTOIMMUNE DISEASE; DISEASE COURSE; DISEASE SEVERITY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNIZATION; INFECTION PREVENTION; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; PROGNOSIS; SARCOIDOSIS; SYMPTOMATOLOGY; TREATMENT PLANNING; VIRUS HEPATITIS; VIRUS TRANSMISSION;

EID: 0038827204     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
2. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881-886.
3. Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine. 2002;20:1699-1701.
4. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327:453-457.
5. National Center for Infectious Diseases. Viral hepatitis. Available at: http://www.cdc.gov/ ncidod/diseases/hepatitis/index.htm. Accessed April 28, 2003.
6. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12,2002. Hepatology. 2002;36:(5 suppl 1):S3-S20.
7. Bresters D, Mauser-Bunschoten EP, Reesink HW, et al. Sexual transmission of hepatitis C virus. Lancet. 1993;342:210-211.
8. Marincovich B, Castilla J, Del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003;79:160-162.
9. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452-1457.
10. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395-1406.
11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349:825-832.
12. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46.
13. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-S56.
14. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593-602.
15. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346:1051-1055.
16. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
17. Kim AY, Chung RT, Polsky B. Human immunodeficiency virus and hepatitis B and C coinfection: pathogenic interactions, natural history, and therapy. AIDS Clin Rev. 2000-01:263-306.
18. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995; 9:1131-1136.
19. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933-941.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
21. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36:S145-S151.
22. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002;36:S128-S134.
23. Stedman C. Herbal hepatotoxicity. Semin Liver Dis. 2002;22:195-206.
24. Zdilar D, Franco-Bronson K, Buchler N, et, al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000;31:1207-1211.
25. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-982.